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This master thesis is a research project and is a part of a larger study called 
“​Molecular biomarkers in oral premalignant and oral cancer lesions”.  
 
Background: Activation of mTOR pathway has been described as a common event 
in oral squamous cell carcinoma (OSCC) and expression of phosphorylated-S6 
protein (pS6), one of the end-point indicators of the activation of mTOR pathway, has 
been shown to correlate with progression of OSCC in cohorts of patients from 
western world. 
 
Aim: The aim of this study was to investigate pS6 as a putative predictor of OSCC 
progression in a cohort of patients from Nepal, with different demographic 
characteristics and etiological factors than the western cohorts previously 
investigated. 
 
Materials and methods: Our cohort consists of tissue samples collected from the 
Nepalese population between the years ​2011- 2014 ​(N = 71) after ethical approval 
from the regional authorities and informed consent from patients. 
Immunohistochemistry containing primary rabbit polyclonal antibodies and​ Dako En 
Vizion visualization system​, were used to examine the expression of pS6. ​SPSS 
statistical package was used in this study to detect associations between pS6 
expression with the 5-years survival rate (statistically significance: p-value <0.05) in 
cases of OSCC and clinico-pathological parameters.  
 
Results: Age (p=0.006), lymph node metastasis (p=0.032) and stage (p=0.004) were 
found significantly associated with overall survival in Kaplan-Meier survival analysis. 
Only age and tumor stage, according to Cox-regression analysis, were independent 
predictors of overall survival. Gender, tobacco and alcohol misuse were not found 
associated with survival. The mean percentage of pS6 expressing tumor cells in the 
tumor center was 53.92% (SEM ± 3.86) with a higher value at the tumor invading 
front where the mean percentage was 56,43% (SEM ± 7.20). The percentage of 
positive pS6 cells in the tumor center were further analysed for correlations with 
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clinical parameters. A weak inverse correlation was found with lymph node 
metastasis (p= 0.028, Pearsons’ r=-0.287). A trend for increased percentage of pS6 
positive cells with tumor size and late stages, as well as in tissues from patients who 
died during the follow-up period, although this was not statistically significant 
(p>0.05).  
 
Conclusions: Our results demonstrate that the activation status of mTOR pathway is 
present in many of the Napalese OSCC cases. Although the investigated samples 
show a high percentage of pS6 expression, pS6 as a cancer biomarker, does not 
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1. Background  
 
1.1 Definition of oral squamous cell carcinoma (OSCC) 
OSCC is one of the most common types of malignant oral cancer arising from the 
oral mucosal epithelium. This mucosal change makes up over 90% of the incidents 
of oral cancer (1). The 5-year overall survival of OSCC is considered to be 47%, 
while the disease-free survival rate is 74% (91).  
 
1.2 Epidemiology  
Head and neck cancers include areas in pharynx, larynx, nasal cavity, paranasal 
sinuses and oral cavity (2).​ Oral cancer is ranked as the 6th most common cancer 
type in the world. ​In India the prevalence of oral cancer is especially high, being the 
second country globally with the highest incidence of oral cancer cases (3). This can 
be explained by the presence of different etiological factors​. Nepal is ranked as 
number 17 in the world (4) and within the country oral cancer is registered as the 8th 






Figure 1:  
Oral cancer ranked as the 6th 
most common type of cancer 
worldwide (3), the 5th in 
South-East Asia (6), the 8th in 
Nepal (5) and the 21st in Norway 
(7). The sources are respectively 








1.3 Geographic facts of Nepal 
Nepal is located in the south of Asia, it borders China in the north and India in the 
west, east and south. Even though the country's total area is 147 180 km², which 
means its size is just above ⅓ of Norway´s total area, the country has a population of 
30 327 877 people and agriculture makes up 75% of the population´s livelihood​ (8, 
9).  
 
1.4 Socioeconomic status in Nepal 
According to the rating of the Human Development Index provided by The United 
Nations, Nepal ranks as number 145 out of 186 countries whereas 186 is the poorest 
developed country in the world regarding social and economic standards (10)​.​ A 
large portion of the population lacks health insurance to pay for medical treatments 
(11). As a result, it is reasonable to think that many people choose to give low priority 
to dental care, as it is not often categorized as life threatening. 
 
1.5 Etiology/risk factors associated with OSCC  
Oral cancer is a complex and multifactorial disease. Some generally known factors 
that increase the risk of oral cancer are: Smoking and smokeless tobacco, excessive 
alcohol consumption, bad oral hygiene and overexposure to sunlight (3).  
 
1.5.1 The role of tobacco and alcohol consumption on OSCC 
Studies show that there is a correlation between the use of tobacco and OSCC. In 
total, 90% of oral cancers have been estimated to be affected by tobacco and 
excessive alcohol consumption ​(12). 
 
Betel quid is a type of smokeless tobacco that is popular in Asia​ ​(13).​ The reason 
why betel quid may have a higher risk for oral cancer than smoking tobacco, may be 
because it ​contains a different carcinogenic ingredient called 
3-(methylnitrosamino)propionitrile (MNPN)​. It originates from arecoline, an alkaloid in 
the areca nut (14)​. Nevertheless, both smoking and smokeless tobacco use are 
considered harmful to health due to the chemical compounds in tobacco. According 
to the National Cancer Institute, there are 250 substances in tobacco that are 
categorized as harmful (15). The chemical compounds in tobacco that are 
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carcinogenic are known as the tobacco-specific N-nitrosamines (TSNAs) and are 
derived from nicotine, nor-nicotine, anatabine and anabasine (16).  
 
1.5.2 Socioeconomic culture and tobacco consumption in Nepal 
Studies show that there is a greater use of tobacco among the poor and lower 
educated as well as there are more males who consume tobacco, than females in 
Nepal. In 2016 there were 52,3% males who used some type of tobacco while 
females covered 8,4% (17). The cultural norm in Nepal may explain this difference. 
Traditional gender roles are still valued in many households and therefore it may be 
considered to be less acceptable for women to intake tobacco and alcohol (18). This 
is reflected in the number of men and women diagnosed with oral cancer where men 
make up 73% of the OSCC cases in Nepal (89). It has been reported that the 
majority of people in Nepal are diagnosed at an advanced stage of oral cancer (19). 
A contributing factor to this may be that the information related to risk factors of oral 
cancer is limited (20) compared to for instance human immunodeficiency virus (HIV) 
(21), acquired immune deficiency syndrome (AIDS) (21),​ ​ tuberculosis (22) and 
cholera (23). The financial aspect of the medical treatments can be challenging for 
many people, especially in a low-income country such as Nepal. ​Many have 
therefore to go untreated.   
 
Older age groups have similarly been associated with higher tobacco consumption. 
Over the last 10-year period smokeless tobacco has been an increasing trend 
compared to smoking tobacco in Nepal, especially among the age group 35 and 
older (17). 
 




1.6 The Nepalese regulations on tobacco 
Because of the well-known tobacco culture, the Napalese government, directed by 
the Ministry of Health and Population, propositioned a bill called “​Tobacco Control 
and Regulatory Bill 2010​”​. ​The bill got approved in 2011 with the purpose of banning 
the consumption of tobacco in public spaces and private sales of cigarettes. Tobacco 
firms must cover 75% of their products with health warnings. All sales of tobacco are 
taxed, and tobacco advertisement is forbidden (27). 
 
1.7 Normal oral mucosa 
1.7.1 Clinical features 
The clinical signs of an ideal healthy oral mucosa are tissues that appear 
symmetrical, with even, smooth surfaces that have a pink tone and are moisty (28). 
High levels of melatonin might be also common, and it will represent itself as areas 
of hyperpigmentation (29). However, irregularities that occur in the oral mucosa are 











Figure 3: A) ​A clinical photo of Fordyce's granules. Published with the permission of Prof. Anne 
Christine Johannessen (30).  ​B)​ Leukoedema observed clinically. Adapted from (31). 
 
Topographical variations are found in oral mucosa. There can either be keratinized 
or non-keratinized epithelium. The areas that fall under the first are masticatory 
mucosa such as gingiva, hard palate and dorsum of the tongue. Non-keratinized 
epithelium can be found in lining mucosa such as lip mucosa, soft palate and buccal 
mucosa. Alveolar mucosa, the floor of the mouth and the ventral surface of tongue 
are also non-keratinized areas in the oral cavity (32, 33). Moreover, frictional 
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keratosis in areas of mucosa that is normally non-keratinized may arise due to 
continuous traumatic external stimuli (34). Non-keratinized epithelium tends to look 
softer and slightly darker in colour compared to keratinized mucosa, as the blood 
vessels underneath are more visible due to the lack of the superficial layer. 
 
1.7.2 Histological features 
The oral cavity has a protective barrier on the surface which is covered by stratified 
squamous epithelium, while the deeper layer consists of lamina propria. These two 
layers are what make up the oral mucosa. As mentioned above, the epithelium can 
either be keratinized or non-keratinized. It can further be divided into different layers 
(35). The main layers being: 
 
- Stratum basale  
- Stratum spinosum / prickle layer 
- Stratum Granulosum (keratinized) 




Figure 3:​ Histological image of the different layers in oral mucosa, keratinized and non-keratinized.  
A)​ Orthokeratinized epithelium: Characterized by the loss of nuclei in the keratinized layer. ​B) 
Parakeratinized epithelium: Characterized  by the presence of nuclei in the layer of keratinization.  
C)​ Non-keratinized epithelium. Adapted from (36).  
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Figure 4: ​Oral lesion with premalignant potential (OPMD) in the form of speckled leukoplakia, 
observed in a patient who chews betel quid. Brown staining on the teeth is a result of the betel quid. 
Adapted from (37). 
 
One of the most common oral lesions with premalignant potential (OPMD) is 
leukoplakia (34). About 10-15% of leukoplakias develop into oral cancer (38). 
Idiopathic leukoplakia has been defined by Regezi et al. as a “white lesion or plaque 
of the oral mucosa that cannot be rubbed off and cannot be characterized clinically 
as any other disease” (39).  
 
1.8.1 Clinical features  
Leukoplakia can appear as shallow lesions located on the oral mucosa, gingiva 
or/and the tongue. This mucosal change has a white appearance due to keratosis, 
with or without hyperplasia of the epithelium. Combined white and red lesions called 
erythroleukoplakia lesions and erythematous lesions called erythroplakia, may 
indicate the potential for cancerous development due to greater risk of being 
dysplastic (40). Although leukoplakia are mostly benign, some patients may 
therefore experience lesions that develop into malignancy. Leukoplakia is usually 






1.8.2 Histological features 
Microscopically, leukoplakia may either have a normal dysplastic or a cancerous 
appearance​. ​Dysplasia signifies disordered growth and abnormal epithelium which 
can further manifest in certain histological characteristics such as: (i) drop-shaped 
epithelial ridges, (ii) basal cell crowding, (iii) irregular stratification, (iv) increased and 
abnormal mitotic figures, (v) premature keratinization, (vi) nuclear pleomorphism and 
(vii) increased nuclear-cytoplasmic ratio. If there is dysplasia, the degree of epithelial 
dysplasia indicates how far the lesion has progressed, in terms of the extent to which 
the abnormal cells have replaced the normal epithelial cells. When the cells have 
penetrated the basal cell membrane, causing an infiltrative growth pattern, the 
patient will get the diagnosis of OSCC. Carcinoma in situ/severe dysplasia is the 
stage right before an invasion of abnormal epithelial cells into the underlying 




Figure 5:​ Illustrating possible development outcomes of hyperkeratosis lesions. Adapted from (38). 
 
1.9  OSCC  
1.9.1 Clinical features 
OSCC can be located on the lips, gingiva, tongue, mobile part of the tongue, hard 
and soft palate, floor of the mouth and inside of the cheeks (43). The symptoms that 
may occur are mouth pain, ear pain or sore mouth, and lesions that do not heal. 
White/red patches inside of the mouth, loosening of teeth and a growth/lump inside 
the mouth are also symptoms that can occur (44). The lesion may become more 
prominent with rolled borders with necrosis at the center (Figure 6). These ulcers 











Figure 6:​ Advanced squamous carcinoma. Ulcer with 
rolled border and necrosis at the center. Surrounding 




1.9.2 Histological features 
OSCC is a pathological infiltrative growth of the oral mucous membrane, due to 
abnormal epithelial cells invading their surrounding tissue. After the abnormal cells 
penetrate the basal cell membrane they will form malignant tumor islands in the 
surrounding connective tissue and/or tissue of muscle (45). The tumor cells will 
induce development of their own blood vessels for nutrition (46). The patient's 
immune system is usually responding to the presence of cancer and this is usually 
observed as inflammatory cells infiltrate in the tumor stroma, as seen in the 
histological figure 8. The cancer cells are irregular and do not follow an organised 
structure, unlike normal epithelial cells (45). 
  
 
Figure 7:​ Histological image illustrating the stages of dysplasia resulting in OSCC and its appropriate 














Figure 8: ​A representative 
picture from one of the 
patients in our cohort 
illustrating an increased 
amount of inflammatory cells 




OSCC can be divided into 3 grades. The grading system is based on the 
differentiation of the malignant cells, meaning their ability to differentiate and produce 
keratin (48). 
  
Well-differentiated OSCC, low grade 
Well differentiated OSCCs contain cells that  
can undergo a differentiation process similar  
to normal oral cells. These cells form keratin 
pearls. ​Compared to poorly differentiated  
cells, they usually spread and grow slower, 





                                                                                                  Figure 9: ​A hematoxylin-eosin stained 
……………………………………………………………………….​slide of tumor tissue with a keratin pearl 




Moderately differentiated OSCC, intermediate grade 
Being in the intermediate grade means that these cells have less ability to 
differentiate than the normal oral epithelial cells. Compared to well-differentiated 
OSCC, the moderately differentiated OSCC have less keratinization, more nuclear 
pleomorphism and higher mitotic activity. This comparison with these cells is 
opposite for the poorly differentiated cells. It has been reported that cases of 
moderately differentiated OSCC had a high recurrence rate (49).  
  
Poorly differentiated OSCC, high grade 
These OSCC contain more pleomorphic cells and have a more irregular form and 
they have little to no keratin formation. In most poorly differentiated carcinomas, the 
cytoplasm of the tumor cells is sparse and less visible. These cells have a tendency 
to metastase and infiltrate a larger portion of the surrounding tissue at an early 
















                    Figure 10: ​Squamous carcinoma containing poorly differentiated cells with 








1.10 Tumor - Nodes - Metastasis (TNM) 
1.10.1 TNM classification of malignant tumors 
There is a standard system that is used to classify the extent of tumors, by 
examining the size and its spread into surrounding tissue. The higher the value is, 
the more severe the tumor is. This results in poorer prognosis and a more invasive 




What stage the tumor has progressed to depends on the combined TNM-values, as 





Tumor stage 1:  ​T1, N0, M0 
Tumor stage 2:  ​T2, N0 or N1, M0 
Tumor stage 3:  ​T3-1, N0-1, M0 
Tumor stage 4​:  T4, N0-1, M0 / T any, N2-3, M0 / T any, N any, M 
 
1.11 Treatment of idiopathic white patches (leukoplakias) and OSCC 
  
Figure 11: ​Showing a standard treatment pathway for idiopathic white patches after biopsy based on 
diagnosis. Adapted from (52). 
 
The treatment of OSCC depends on the severity of the tumor. If the clinical 
practitioner suspects the tumor or the idiopathic white patches to be malignant, then 
the patient should be referred to a specialist - that would be to the regional head and 
neck oncological team. Where a biopsy will be taken to give the lesion a diagnosis. 
If the practitioner has a low suspicion of the lesion being malignant the lesion can be 
observed (maximum 2 weeks). If the lesion progresses, a biopsy will be necessary 
for diagnostics. If it is indicative of malignancy, the patient will be referred to the 
regional head and neck oncological team for further evaluation. 
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Surgery is the preferred method for carcinomas that are small and easily accessible, 
verrucous or involve bone and have a high risk of later radionecrosis because of 
radiotherapy. However if the tumor responds poorly to surgery or metastasis to other 
areas that are less accessible, another option is to combine surgical treatment with 
radiotherapy.  
Radiation therapy will give a more acceptable aesthetic and functional result 
compared to surgery, however it will also provide discomfort during the multiple 
treatment sessions. The downside of this treatment form is that radiation will damage 
the patient's normal cells as well as the neoplastic cells. Localizing and separating 
the healthy from the neoplastic tissue is therefore a crucial part of the treatment 
planning (53). 
Chemotherapy is another treatment option for oral cancer. The treatment uses drugs 
containing cytotoxic agents. They can either be the primary therapy or it can be 
combined with radiation therapy and thereby be a radiation sensitizer. The latter 
gives a better survival rate for patients with extracapsular nodal extension and 
positive resection margin. For many cancer types that might especially have a high 
risk of recurrence and metastasis, adjuvant chemotherapy is given after the surgery 
to prevent this (54). However, for head and neck cancers this had not shown to give 
any benefits according to a meta-analysis of chemotherapy in head and neck cancer 
(55).  
In Immunotherapy the patient's own immune system gets stimulated to be able to 
attack tumor cells. The immune system has checkpoints that regulate apoptosis, 
maintain homeostasis and prevent autoimmunity (56). Cancer cells survive by 
avoiding these checkpoints. Tumor cells have proteins on the surfaces that bind to 
immune checkpoint proteins located on the surfaces of the T-cells. This binding 
results in the T-cell getting inactivated, leading to the continued survival of the tumor 
cell (57). Prembrolizumat (keytruda) and Nivulomab (opdivo) are drugs used for the 
treatment of head and neck cancers. Their role is to inhibit this binding, and thereby 
allowing the T-cell to eliminate the cancer cell. In head and neck cancers, the use of 




1.12 The pathogenesis of OSCC 
The development of OSCC has been reported by many studies to be caused by 
multiple genetic alterations in key genes controlling cell proliferations and survival 
(59, 60). These mutations are believed to cause dysregulation in cell proliferation 
and survival affecting cell invasion and metastasis. Further discovery has shown that 
most of these gene mutations take part in four major driver biologic processes. In 
2013, Pickering and colleagues reported these four biologic processes (60): 
 
(i) Mitogenic signaling was altered in 63% of the tumors. 
(ii ) Defective cell differentiation (9% NOTCH1 gene mutation and 66% predicted 
NOTCH signaling route alterations). 
(iii) Nearly universal cell cycle-deregulation (94%). 
(iv) Genomic instability, FAT1 (30%) and CASP8 (10%) due to the lack of candidate 
genes involved in detecting and repairing DNA damage, such as TP53. 
  
Out of the four major driver biologic processes mentioned above, studies have 
shown that the PI3K pathway, a mitogenic signaling route, is harbouring the most 
genetic mutations in the head and neck cancers (60). This thesis about OSCC has 
therefore aimed to investigate the activation of the PI3K (mTOR) pathway and its 
putative role for prognosis. 
 
1.12.1 mTOR pathway 
mTOR is a serine/threonine protein kinase; a family member of the phosphoinositide 
3-kinase (PI3K)-associated protein kinase, which has a key role in the cell 
physiology, as it is being involved in multiple cellular functions in the human body. In 
response to environmental cues from nutrient and hormonal stimuli, this protein 
kinase regulates the cell´s cytoskeleton, autophagy, metabolism, growth, 
proliferation and survival (61). Its activity has therefore further been reported to affect 







1.12.2 mTORC1 and mTORC2 
mTOR is a physical target of Rapamycin, which is a compound with the ability to 
prevent cell growth and proliferation by inhibiting signal transduction pathways 
(62).The mTOR component is made out of two protein complexes called mTOR 
complex 1 (mTORC1) and mTOR complex 2 (mTORC2). They have different 
sensitivities to Rapamycin; mTORC1 being sensitive to the compound whereas 
mTORC2 mostly being insensitive to it (61). 
  
First, mTORC1 integrates growth factors, ATP production, oxygen levels and amino 
acids, which are all important signals in biologic processes. The downstream targets 
of this specific protein complex have in turn the ability to regulate cellular growth and 
proliferation due to it  being involved in protein synthesis, biosynthesis of lipids, 
autophagy and energy metabolism. The protein synthesis is promoted by mTORC1´s 
direct phosphorylation of S6 kinase 1 and the eukaryotic translation initiation factor 
4E (eIF4E) binding protein 1 (4E-BP1). This enables 4E-BP1 to bind to the 
cap-binding protein elF4E. The elF4E complex will further initiate the cap-dependent 
mRNA translation. Cell division and proliferation is dependent on the protein 
synthesis. Second, mTORC2 is mainly affected by growth factors, and it controls 
cellular survival, metabolism and cytoskeleton organization by activating the Akt 









Phosphorylation is a mechanism in cellular processes that regulates protein function 
and signal transduction pathways (64). Both protein complexes have the ability to 
catalyze the phosphorylation of different substrates. Protein S6, which is a 
compound of the 40S ribosomal subunit, plays an important part in translation and 
protein biosynthesis as it is one of the downstream effectors of mTORC1 (65). 
  
S6 can, during the mitogenic stimulation, get phosphorylated at their serine residual 
sites, such as Ser-235, Ser-236, Ser-240 and Ser-244 - those being reported as the 
key downstream effectors of mTORC1 activity (66, 69). The phosphorylation step is 
done by the upstream components, comparatively the p70S6 kinases and the p90 
ribosomal S6 kinases (67). 
  
1.12.3 Dysregulated mTOR pathway 
In certain human diseases, such as OSCC, the mTOR pathway is dysregulated, 
respectively in 90 -100% of all head and neck cancers (68, 84). When it is an 
aberrant activation of the phosphorylation of S6 in the (PI3K)/mTOR pathway, it can 
cause genetic alterations in head and neck cancers. The protein has also the ability 
to get phosphorylated by mTOR-independent pathways such as oncogenic 
Ras/extracellular signal-regulated kinase (ERK), tumor promoting phorbol esters, 
serums and growth factors (69). However, the PI3K/mTOR pathway is considered to 
be the most frequently activated signaling route in head and neck cancer (60, 87). 
According to a research published in 2013, it was reported that activation of the PI3K 
pathway caused by genetic mutations had the highest percentage (30,5%) compared 
to other mitogenic signaling pathways, such as MAPK and JAK-STAT (>10%) in the 
head and neck. PIK3CA was registered as the most mutated gene in the network, 
covering 12,6% of the alterations. Overall, this may indicate that the maintenance of 
the activation of the malignant conditions causing different genetic changes, 





              Figure 13: ​Demonstrating the oncogenome of head and neck cancer with alterations  
              in the key genes. Adapted from (70).  
 
  
1.12.4  pS6 as a cancer biomarker 
The amount of pS6 in a cell marks its mTORC1 activity (71). pS6 has therefore been 
used as a cancer biomarker for detecting the status of activity in the mTOR pathway 
in cases of OSCC. Studies have found overexpression of pS6 being present in 
different human cancers including cases of OSCC and further the possibility of pS6 
being significant for the evaluation of prognosis (72-75). For instance in one of the 
studies, expression of pS6 was detected in 100% of the cases of dysplasia and 
within these there were 88,67% of OSCC cases. Only 50% of cases of normal oral 
mucosa were reported to display pS6 expression (73). Low expression of pS6 has 
further been reported to cause reduction in biologic processes such as cell 
proliferation, cell growth and protein synthesis (76)​. Nevertheless, all this data has 
been generated on cohorts of patients from the western world. None investigated 
pS6 expression in OSCC cohorts from other parts of the world. 
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2. Hypothesis and specific aims of the study 
  
2.1 Hypothesis 
Deregulation of the mTOR pathway is a common molecular event and the 
expression of pS6 can be used to evaluate the prognosis of patients with oral 
squamous cell carcinoma in South Asia as well. 
  
2. 2 Specific aims 
1. Examine the expression of p6S in formalin fixed paraffin embedded (FFPE) 
material of OSCC from a cohort of patients from Nepal. 
2. Examine the correlation between the expression pattern of pS6 and the 
clinicopathological parameters and survival of OSCC patients from a cohort of 
patients from Nepal. 
 
  
3. Methods and statistics 
 
3.1 “​Molecular biomarkers in oral premalignant and oral cancer lesions”: An 
ongoing project 
The tissue material that was used for this study was retrieved between the years 
2011- 2014 and it came from Nepalese patients. The Ethics Committee for Medical 
and Health research in West Norway (2011/1244 REK vest) and Nepal Health 
Research Council (ref.526/2012) had approved the use of the material. This study is 
a part of a bigger and ongoing project called, “Molecular biomarkers in oral 
premalignant and oral cancer lesions''. Tissues were collected after the patient's 
consent. 
 
3.2 Inclusion and exclusion criteria 
Several criteria had to be fulfilled for the specimens to be included in the study: The 
patients had to have a confirmed diagnosis of OSCC and be above 18 years old. 
They should not have received any prior treatment with chemotherapy or radiation 




The patients that fell outside these criteria were not included in the study. This 
included patients who would not give their consent, cases where relevant clinical 
data were missing, such as use of smoking and alcohol or cases that were positive 
for HPV infectio​n.​ Some tissue samples that were originally part of the cohort, had to 
be excluded during quantification (10 specimens). Because the specimens were torn 
by the staining procedure or due to the presence of too many inflammatory cells 
(leukocytes) in the specimen and thereby making the areas for analysis not 
representable. 
 
3.3 Description of cohort 
The clinicopathological parameters in this study are age, gender, alcohol and 
smoking habits, tumor differentiation, tumor stage and lymph node metastasis. 
 
 
Tissue specimens from 71 patients 
were used in the study. The samples 
were taken from various regions of the 
oral cavity, such as ​buccal mucosal or 
gingiva (63.9%), tongue (31.1%)  
and floor of the mouth (4.9%).   
 
 
Of the 71 specimens, 10 were excluded due to the reasons mentioned earlie​r. ​This 
resulted in 61 approved tissue samples that could be used to examine the 
expression of pS6. The cohort consisted of 13 females and 48 males, between the 
ages of 35-75 (mean age 56) with varying use of alcohol (65,6% misused alcohol) 
and smoking (36,1%). Of the 61 patients, ​29.5% were still alive at the end of the 
study (5 missed values). Figure 15 A ​illustrates the distribution of the substance use 













Figure 15:  A) ​Table representing the patients tobacco and alcohol habits. ​B)​ Pie chart demonstrates 
the gender distribution within the cohort. 
  
 
Most of the patients presented with big tumours (54.1% with T4, 26.2% with T3, 
16.4% with T2 and 3.3% only with T1); 85.2% were at a late stage, but only 42.6% of 




Figure 16:​ Distribution of tumor sizes, cases of late stage and early stage, cases with and without 





Most of the cases were well-differentiated OSCC, as shown in Table 2. All of the 
cases presented here are valid, meaning only cases with all of the variables 
available were included. The variables being age, gender, smoking/non-smoking, 
alcohol/non-alcohol, differentiation and metastasis status. 
 
 
Figure 17: ​The table shows the different differentiation levels. ​Frequency:​ The number of cases within 
its respective category. ​Percent​: Frequency represented as percentage. ​Valid percent​: The 
percentage of cases left when cases with missing clinical data were exclude​d. ​Cumulative percent​: 
























Valid High 38 62.3 62.3 62.3 
Medium 20 32.8 32.8 95.1 
Poor 3 4.9 4.9 100.0 




The preferred method to examine the expression of pS6 in carcinogenic cells is 
immunohistochemistry (IHC). The technique builds upon the antibody's ability to bind 
to its complementary antigen which in turn will give us the necessary information 
about the distribution and localization of PS6 protein. ​This technique is a 
well-established method, with its own advantages and disadvantages. The 
advantages being that it is possible to use both fresh and formalin fixed samples. 
Since our tissues come from Nepal, formalin fixed paraffin embedded (FFPE) 
samples were used.​ The procedure is inexpensive, but the equipment needed is 
costly, although IHC could also be done manually, making it an affordable method 
that can be used in low-income countries. Infectious agents are dead, and there is 
no risk to human health. The disadvantage of IHC is that the method is sensitive, 
exposed to human errors and the quantification of the results can be difficult.  
 
3.5 Protocol 
The protocol for pS6 was adopted from an existing master’s thesis on International 
Health from University of Oslo (UIO). About 4-5 microns thick sections of the FFPE 
were used for IHC. The sections were afterwards placed on glass-slides and 
incubated at 56°C​ ​ for 1-2 hours. This will make the tissue adhere better to the 
glass-slides.  
 
3.5.1 Deparaffinization and antigen retrieval procedure 
The first step after incubation is to remove the paraffin which the tissue sample is 
embedded in. For this, the glass-slides were placed in a Xylene solution and later in 
Ethanol. The next step is to expose the tissue’s antigens by boiling the slides in a 
Citrate-buffer with pH 6. The high temperature will break the bridges made by 
formalin between the proteins in the fixed tissue, and thereby expose the desired 
protein, in this case pS6. 
 
3.5.2 Choice of dilution 
Before having all the tissue samples exposed to IHC, four went through the staining 
protocol to determine which dilution would be sensitive enough to stain the relevant 
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protein in the cancer cells. For this we used two different antibody concentrations, 
1:100 and 1:200. The result showed that 1:100 was specific and sensitive enough. 
Negative and positive controls from breast cancer tissue were also included. 
 
3.5.3 Primary and secondary antibody 
To examine the expression of pS6, specific primary rabbit polyclonal antibodies were 
used. Primary antibody is the first antibody that binds to the antigen in the tissue. 
The secondary antibody, which is a part of a complex consisting of a polymer 
backbone (dextran) and enzymes, binds to the primary antibody (77). The enzymes 
in the complex are the structures that will convert 3,3’ diaminobenzidine (DAB) 
chromogen to a compound with a brown colour and thereby resulting in the visual 
exposure of pS6. The purpose of using “peroxidase block” is to inactivate the 
peroxidase enzyme in the tissue to prevent it from being stained by 3,3′-(DAB) which 





























3.6 Scanning of slides and digital quantification of IHC stained slides 
  
3.6.1 QuPath cell detection 
To quantify the cells with cytoplasm/membranous staining, we used QuPath 
open-source software created by the Center for Cancer Research and Cell Biology, 
Queen's university Belfast (80).​ ​The purpose of the quantification is to find the 
percentage of the number of positive cells, meaning the amount of the expression of 
pS6. Before quantification certain parameters, such as brightfrield (H-DAB), 
magnification and brush tool had to be standardized. Two layers from the basal cell 
membrane and a minimum of 1000 cells were required per slide. The areas that 
should be evaluated for expression of pS6 were tumor front and tumor center. 
 
 
 Figure 21: ​The “positive cell detection” function in QuPath  





3.6.2 Tumor invading front 
Tumor front is topographically defined as the area of invasive tumor islands and the 
underlying stromal tissue situated at the outmost 200​ ​μm​ of the tumor from the most 
invasive cells. This was firstly demarcated with a guideline. 
  
Tumor front is characterized by aggressive tumor cells that are poorly differentiated. 
These cells infiltrate surrounding tissue and show a high grade of cell dissociation. It 
is therefore believed that the tumor front is the most relevant part of  a tumor to be 
analysed when investigating biomarkers for prognosis (81). 
 
3.6.3 Tumor center 
The area of the tumor center is generally composed of cells that are more 
differentiated cancer cells, which means that they are often organized in networks 
containing tumor islands and keratin pearls. Keratin pearls usually do not have the 
same amount of nutrients as the cells in the tumor invading front. Cases where there 
is too little nutrients can result in necrosis which can often be detected in especially 
large cancers. The tumor center reflects therefore more the history of a tumor while 
the tumor front is the most active and new part of a tumor and thus might better 
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Figure 23:​ Showing a keratin pearl in high pS6  





4.1 Clinical-pathological correlations and survival analysis 
Age (p=0.006), lymph node metastasis (p=0.032) and stage (p=0.004) were found 
significantly associated with overall survival in Kaplan-Meier survival analysis. Cox 
regression showed that only age and stage were independent predictors of overall 
survival. People who were 56 years or younger had a longer survival rate than those 
who were older (Figure 24). The same pattern was found with lymph node 
metastasis (Figure 25) and stage (Figure 26), where the presence of lymph node 


























Figure 24:​ Demonstrates the survival rate according to age. Value 1.00 indicates patients aged 56 
and under, while 2.00 represents patients older than age 56. 1.00-censored represents people aged 


















Figure 25: ​ Demonstrates the survival rate of people with and without lymph node metastasis. 
No-censored represents people without lymph node metastasis, who did not survive, while 




















Figure 26:​ Illustrates that the prognosis is significantly better by diagnosis at an early stage of OSCC 
compared to diagnosis at a late stage. Early-censored and late-censored symbolizes the people who 
died.  
 
Gender, smoking or alcohol misuse were not found associated with survival, as 








Figure 27: ​ ​A)​ Graph illustrates survival rate of OSCC among male and females. ​B)​ Graph 
demonstrates the survival rate of OSCC among non-tobacco and tobacco users. ​C)​ Graph illustrates 










4.2 Description of pS6 staining 
Immunohistochemistry  allowed the tumor cells that contained pS6 to be visible by 
staining them brown. Cells that were negative for the expression of pS6 remained 
blue. Various amounts of pS6 expression were found in all 61 cases both for tumor 
center and tumor invading front. In most of the cases the expression was located in 
the basal epithelial layer, however structures surrounding them such as salivary 









Figure 28: A) ​Illustrating a tumor island with mostly negative pS6 expression in the quantified area  
(black arrow). Positive pS6 expressed stroma is however quite visible. ​B) ​Demonstrating quantified 
areas of tumor center with a high amount of pS6 positive cells. ​C) ​Showing​ ​a tumor island with both 
positive and negative pS6 expressions. 
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4.3 Expression of pS6 
The 59 cases were quantified to identify the amount of positive pS6 cells in the tumor 
center. Only 22 of these 59 cases presented a tumor front, and pS6 was also 
quantified at tumor invading front in these cases. Results showed that the mean 
percentage of pS6 expression in the tumor center was 53.92% (SEM ± 3.86) with a 
higher value at the tumor invading front where the mean percentage was 56,43% 
(SEM ± 7.20). The standard deviation of the mean within a dataset is an indication of 
the spread of data, the smaller the value, the more accurate the dataset. The data 







The black curves in graph B and C, represent the normal distribution of positive cells. 
According to graph B, the percentage of positive cells were relatively normally 
distributed for tumor center. This pattern was not seen at tumor invading front, as 
demonstrated in figure 29 graph C. Here the percentage of positive cells curved 
towards the high value spectrum. The median is used as a measure of centrality and 
it is more stable to extreme observations in terms of measure errors when finding the 
mean value, compared to the average. In this case, the median was found to be 
51.45 for pS6 in the tumor centre and 57.99 for pS6 in the tumor invading front, 

























Figure 29: Table A)​ Cohort statistics regarding the expression of pS6.  ​B) ​The distribution of ps6 
expression in tumor center. ​C)​ The distribution of positive ps6 cells in the tumor invading front. 
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To discover any possible existence of correlation between two values, those being 
pS6 centre and pS6 invading in this case, data in SPSS for Pearson´s r, Sig 
(2-tailed) and N value were used. The results showed generally higher percentages 
at the tumor front than in the center of the same tumor. However a strong correlation 
between the percentage of positive cells in both tumor invading front and tumor 




Figure 30: ​Table illustrating the values for interpreting the correlation between tumor 
center and tumor invading front regarding pS6 expression. 
  
 
Because there were very few (n=22) cases with quantifiable tumour invading front, 
further analysis of this region would not provide a representable outcome. Statistics 
illustrated below demonstrate therefore values retrieved from analysis performed 






  pS6 centre pS6 invading 
pS6 centre Pearson Correlation 1 .806​** 
Sig. (2-tailed)   .000 
N 59 20 
pS6 invading Pearson Correlation .806​** 1 
Sig. (2-tailed) .000   
N 20 22 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
4.4 Correlations of % pS6 positive cells with clinical parameters and 
overall survival 
 
The analysis showed that the clinical parameters, such as age, gender, smoking and 
alcohol use and tumor characteristics, had no correlation with the percentage of 
positive pS6 cells.  It did however present a weak inverse correlation with lymph 
node metastasis (p= 0.028, Pearsons’ r=-0.287). ​Figure 29 table A shows that the 
percentage of positive cells in the tumor center, within the 25 % of the patients who 
had the lowest occurrence of percentage of positive cells, was 26.5%. In the bar 
chart below, the patient cohort was divided into two groups (red=1.00 and blue=.00). 
The red signifying patients with higher than 26.5% pS6 positive cells, whereas blue 
represents patients with the percentage of positive cells equal to 26.5% or less. 
There was higher pS6 expression among patients who had N2 compared to N1. ​A 
similar comparison in amount of pS6 expression between the groups was observed 
for patients without lymph node metastasis as well. There were also registered more 
cases of pS6 expression for patients who had no lymph node metastasis in the red 












Figure 31: ​Bar chart representing the expression of pS6 in patients with positive and negative lymph 
node metastasis. Results showing patients with no metastasis having a higher percentage of pS6. 
  
An increase in tumor size, showed an increase in the expression of pS6. The same 
pattern was found in cases where the tumors were in late stages as well with 
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Figure 32: A)​ Illustrating tumor size being proportional to expression of pS6​.  B) ​Bar chart 
demonstrating that cases of later stages grow in proportion to positive ps6 expression.​ C) ​Indicating 
an increased level of ps6 expression for candidates who died before completing the study at 10 years. 
  
 
Buccal and gingiva located cancers had greater expression of pS6 meanwhile 
cancers located in the floor of the mouth had the lowest. Both localization and 









Figure 33: A) ​Bar chart demonstrating the level of pS6 expression among the different cancer sites. 
B)​ Bar chart demonstrating the level of pS6 expression among the differentiation groups. 
  
 
As the graph below demonstrates, patients with a low percentage of pS6 positive 




Figure 34: ​Graph illustrating survival benefits between patients with low and high ps6 expression to 
be of insignificant value. 
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5. Discussion  
 
Oral squamous cell carcinoma is one of the most common types of oral cancer which 
can result in high morbidity and mortality. As for many cancer types, the cells in 
OSCC undergo genetic alterations which lead them to have unpredictable growth 
patterns and thereby are difficult to treat. Studies have shown that many factors take 
part in influencing the prognosis of cancer. Factors such as alcohol intake and 
tobacco use are carcinogenic and will worsen the prognosis (83).  
 
Treatment of cancer has evolved throughout the years and continues to evolve. One 
major problem related to the treatment plans is that they are not cancer-cell-specific 
(53). This results in not only the removal of damaged cells, but also the patient's 
healthy cells. Prognostic biomarkers can help solve this problem. By studying the 
expression of certain proteins in cancer cells, one would learn more about how 
aggressively cancer cells grow and infiltrate surrounding tissue, and thus how 
aggressive the treatment should be. This can in turn help to predict the prognosis 
and decide the extent of the treatment.  
 
An association between pS6 and the pathogenesis of OSCC has been suggested by 
numerous studies through the years. Activation of mTOR pathway followed by the 
phosphorylation of the S6 protein were indicated to be an early and common event in 
the disease. In five investigations by Chakraborty et al. (84), Chaisuparat et al. (73), 
Martins et al. (85), de Vincente et al. (75) and Tamatam (86) who did respective 
analysis of pS6 expression, it was reported higher pS6 expression in cases of 
OSCCs than in normal mucosa. Similar to the previous mentioned studies the 
current project observed high pS6 expression in most of the tissues of OSCC, 
although we did not compare the levels in OSCC lesions with the levels in the 
adjacent normal mucosa, due to lack of normal mucosa tissues in our tissue 
samples. This indicates that the mTOR classical pathway is also activated in the 
OSCC lesions from patients from South Asia, with similar demographic 




Contrasting the study by Tamatam (86), the mean percentage of pS6 expression 
was found to be higher at tumor invading front (56.44%) compared to tumor center 
(53.9%) (Figure 29 A). Although the difference between the two locations was small, 
the observation of greater pS6 expression at the tumor invading front was expected, 
as it is known to be the most active and proliferative of the two. In our study, a 
correlation between high pS6 expression and less lymph node metastasis was 
found. Whether this finding has any biological or prognostic meaning has to be 
further investigated in larger cohorts of patients from similar demographic 
populations. However, a study on a Caucasian cohort of head and neck cancers 
from Spain found also expression of pS6 to correlate inversely with presence of 
lymph node metastasis (87). This controversy needs further investigation.  
 
The distribution of pS6 positive cells in the tumor invading front was not investigated 
for clinical correlations in this study since there were very few cases with tumor front 
and the values were as it skewed toward the high value spectrum (Figure 29 C). A 
greater cohort of patients may give a more expected normal dispersal, as it was 
observed for the values at the tumor center (Figure 29 B).  
 
As statistics earlier demonstrated, age (Figure 24), tumor stage (Figure 25) and 
lymph-node metastasis (Figure 26) were found to predict statistically significant 
overall survival. The explanation for why younger age groups have a better survival 
rate, could be that they have a more effective immune system that is able to combat 
the cancer. Additionally, in those cases, it may be common to observe a highly 
increased amount of inflammatory cells which is often recognized by oral 
pathologists as a positive trait regarding fighting cancer, as the body detects the 
tumor cells as pathological (Figure 8). In addition, the bodies of younger persons are 
also more able to withstand the aggressive treatments available for OSCC (88). 
Patients who presented carcinoma at stage I and II, had also a better survival rate 
than those in stage III and IV. Late stage cancers have progressed in size, lymph 
node involvement and metastasis to surrounding organs. Managing the tumor would 
therefore be more difficult in such late cases. 
  
In agreement with studies on a number of registered cases of OSCC between male 
and female, this cohort provided a similar distribution where the men made up the 
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majority (48 men, respectively 13 female) (Figure 15). This observation supports 
previous reports that there is a trend of more men being diagnosed with OSCC in 
Nepal compared to women (89).  
 
Neither gender (Figure 27 A ), alcohol intake (Figure 27 B ) or tobacco consumption 
(Figure 27 C) were able to predict overall survival in our study. Based on literature, 
chewing tobacco is moderate to low carcinogenic, whereas betel quid with tobacco is 
highly carcinogenic (13). Frequent use increases the cancer risk (15). Since the 
tobacco type and the consumption quantity was not registered, a possible 
explanation for tobacco being statistically insignificant, can be due to low tobacco 
consumption and/or the use of low carcinogenic tobacco among the patients of the 
study. Although it can not be ruled out that the size of the cohort, may be another 
important explanation why the mentioned clinical risk factors above were found not 
to be significant for the overall survival as in other studies. In the study there were 
only 22 of 61 patients who consumed alcohol, whereas 40 of 61 of them used 
tobacco (Figure 15 A). 
 
According to our analysis, there was no statistically significant association between 
the expression of pS6 in tumor center and overall survival (p<0.05), although a trend 
was shown towards higher percentage of positive pS6 cells in bigger tumors and 
patients that died during the follow up period. Similarly, an earlier study has shown 
that there is no significance between positive pS6 in tumor invading front and overall 
survival (86). This might support our findings since we found a strong correlation in 
our study was observed between positive pS6 cells at tumor invading front and 
tumor center. Interestingly, other studies have also detected better survival to be 
correlated with pS6 expression in OSCCs and laryngeal carcinomas (75, 87). The 
different outcome between different studies and ours, might come from the use of 
different antibodies for detection of pS6 and different ways of quantification. 
However, whether pS6 is a prognosticator of better or worse survival is a 
controversial issue and needs further investigation.  
 
Nevertheless, mTOR pathway mutations have been suggested by studies to be a 
predictive biomarker, due to the PIK3CA mutated gene’s different sensitivity for 
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activation of pS6 expression in the mTOR pathway. mTOR-based targeted therapy 




























6. Conclusion  
Our results demonstrate that the mTOR pathway is activated in many of the OSCC 
cases from Nepal, as shown by the high percentage of pS6 positive cells in the 
tissues investigated. However, pS6 does not seem to be a predictor of tumor 
progression or survival in this patient cohort. The value of pS6 as a prognostic 






























7. Limitations  
 
Certain limitations regarding this study were observed. The acquisition of information 
about the overall activation status to mTOR in the current study was limited, as pS6 
only provided information about activation of mTORC1. To get a better 
understanding of oral cancer, the knowledge around the activation status of 
mTORC2 will be required as well.  
 
This project will only provide limited conclusions as it is a retrospective study and it 
was performed on a limited number of cases. In addition, because type and amount 
of tobacco use were not documented among the patients, this brings a limitation 
when interpreting the results from the study. 
 
Extensive research on mTOR investigation on larger cohorts of patients is therefore 
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